State Of Wyoming Syndax Pharmaceuticals Inc Transaction History

State Of Wyoming

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$20.66 - $28.98 $66,979 - $93,953	3,242 New	3,242 $68,000
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $1,888 - $2,528	102 Added 9.01%	1,234 $30,000
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $65,485 - $93,523	-4,801 Reduced 80.92%	1,132 $22,000
Q1 2022 May 13, 2022	BUY	$14.84 - $22.15 $62,046 - $92,609	4,181 Added 238.64%	5,933 $103,000
Q4 2021 Feb 11, 2022	BUY	$15.23 - $22.47 $2,619 - $3,864	172 Added 10.89%	1,752 $38,000
Q3 2021 Feb 11, 2022	BUY	$13.87 - $19.8 $12,080 - $17,245	871 Added 122.85%	1,580 $30,000
Q2 2021 Feb 11, 2022	BUY	$13.42 - $25.18 $9,514 - $17,852	709 New	709 $12,000

229

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $934M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.